Company Description
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally.
The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands.
In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors.
The company was incorporated in 2006 and is headquartered in Redwood City, California.
Country | United States |
Founded | 2006 |
IPO Date | Nov 6, 2014 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 1,215 |
CEO | Kevin Thornal |
Contact Details
Address: 1800 Bridge Parkway Redwood City, California 94065 United States | |
Phone | 650 251 0005 |
Website | nevro.com |
Stock Details
Ticker Symbol | NVRO |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001444380 |
CUSIP Number | 64157F103 |
ISIN Number | US64157F1030 |
Employer ID | 56-2568057 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Kevin R. Thornal | President, Chief Executive Officer and Director |
Roderick H. MacLeod | Senior Vice President and Chief Financial Officer |
Kashif Rashid J.D. | Senior Vice President of Corporate Development and Chief Legal Officer |
Greg Siller | Senior Vice President and Chief Commercial Officer |
Christofer Christoforou | Senior Vice President and Chief Operating Officer |
Angeline C. McCabe | Vice President of Investor Relations and Corporate Communications |
Shana D. Ross M.B.A. | Senior Vice President and Chief Human Resources Officer |
Dr. David Caraway M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
Peter A. Socarras | Vice President, General Counsel and Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Sep 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Sep 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Aug 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |